All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
An oral session on lymphoma took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 19 March 2018. Abstract OS1-2 was presented by Sarah Haebe, from the Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research, Ludwig-Maximilians University, Munich, Germany which compared the safety and efficacy of post-transplantation cyclophosphamide (PTCy)-based haploidentical donor (haplo-D) transplantation versus HLA-matched related donor (MRD) or unrelated donor (URD) transplantation in refractory or relapsed (R/R) aggressive non-Hodgkin lymphoma (aNHL).
In this study, patients treated with T-cell replete (TCR) HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) were matched-paired with patients receiving HLA-matched transplantation (MRD and URD). The age (± 5 years) and the stage at HSCT (defined as complete response [CR] or non-CR) varied between pair-matched patients in this analysis. The primary endpoints of this study were overall survival (OS), progression-free survival (PFS), non-relapse mortality (NRM) and graft-versus-host disease (GvHD) incidence.
The results from this study demonstrated similar outcomes between patients treated with haplo-HSCT using PTCy and patients who received HLA-matched transplantation. With a higher incidence of acute GvHD and NRM rates after URD transplantation, the authors suggested that haplo-HSCT might be used as an efficient safer alternative regimen for patients with aNHL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox